186 related articles for article (PubMed ID: 38770962)
21. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
[TBL] [Abstract][Full Text] [Related]
22. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
23. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Akl EA; Kahale L; Terrenato I; Neumann I; Yosuico VE; Barba M; Sperati F; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006466. PubMed ID: 24980743
[TBL] [Abstract][Full Text] [Related]
24. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
Aronow WS; Shamliyan TA
Am J Ther; 2019; 26(6):e679-e703. PubMed ID: 30461433
[TBL] [Abstract][Full Text] [Related]
25. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Akl EA; Kahale L; Terrenato I; Neumann I; Yosuico VE; Barba M; Sperati F; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006466. PubMed ID: 24897382
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulation for people with cancer and central venous catheters.
Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
[TBL] [Abstract][Full Text] [Related]
30. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
Ezekowitz MD; Pollack CV; Halperin JL; England RD; VanPelt Nguyen S; Spahr J; Sudworth M; Cater NB; Breazna A; Oldgren J; Kirchhof P
Eur Heart J; 2018 Aug; 39(32):2959-2971. PubMed ID: 29659797
[TBL] [Abstract][Full Text] [Related]
31. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
32. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
Siontis KC; Zhang X; Eckard A; Bhave N; Schaubel DE; He K; Tilea A; Stack AG; Balkrishnan R; Yao X; Noseworthy PA; Shah ND; Saran R; Nallamothu BK
Circulation; 2018 Oct; 138(15):1519-1529. PubMed ID: 29954737
[TBL] [Abstract][Full Text] [Related]
33. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
[TBL] [Abstract][Full Text] [Related]
34. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.
Fredman D; McNeil R; Eldar O; Leader A; Gafter-Gvili A; Avni T
J Thromb Thrombolysis; 2024 Mar; 57(3):453-465. PubMed ID: 38127261
[TBL] [Abstract][Full Text] [Related]
36. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
37. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
[TBL] [Abstract][Full Text] [Related]
39. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Schafer JH; Casey AL; Dupre KA; Staubes BA
Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
